Multimorbidity

Last updated

Multimorbidity, also known as multiple long-term conditions (MLTC), means living with two or more chronic illnesses. [1] For example, a person could have diabetes, heart disease and depression at the same time. Multimorbidity can have a significant impact on people's health and wellbeing. It also poses a complex challenge to healthcare systems which are traditionally focused on individual diseases. [1] Multiple long-term conditions can affect people of any age, but they are more common in older age, affecting more than half of people over 65 years old. [2] [3]

Contents

Definition

The concept of multiple long-term conditions is not clearly defined [1] [4] [5] and may be referred to by various names. [6]

Difference from comorbidity

Multimorbidity is often referred to as comorbidity even though the two are considered distinct clinical scenarios. [6] [7] [8]

Comorbidity means that one 'index' condition is the focus of attention, and others are viewed in relation to this. In contrast, multimorbidity describes someone having two or more long-term (chronic) conditions without any of them holding priority over the others. This distinction is important in how the healthcare system treats people and helps making clear the specific settings in which the use of one or the other term can be preferred. Multimorbidity offers a more general and person-centered concept that allows focusing on all of the patient's symptoms and providing a more holistic care. In other settings, for example in pharmaceutical research, comorbidity might often be the more useful term to use. [2] [8]

Definitions

The broad definition of multimorbidity, consistent with what is used by most researchers, the WHO and the UK's Academy of Medical Sciences is the "co-existence of two or more chronic conditions". These can be physical non-communicable diseases, infectious and mental health conditions in any possible combinations and they may or may not interact with each other. [6] When the co-existing conditions have similar origins or treatments the terms used is concordant multimorbidity, while discordant multimorbidity is used to refer to conditions that appear to be unrelated to each other. [6]

Definitions of multimorbidity usually differ in the minimum number of concurrent conditions they require (most often this is two or more) and in the types of conditions they consider. [9] For example the UK's National Institute for Health and Care Excellence (NICE) includes alcohol and substance misuse in their list of conditions considered to constitute multimorbidity. [10]

Naming

The most commonly used term to describe the concept is multimorbidity. However, scientific literature shows a diverse range of terms used with the same meaning. These include comorbidity, polymorbidity, polypathology, pluripathology, multipathology, multicondition. [11]

The UK's National Institute for Health and Care Research (NIHR) uses the term multiple long-term conditions (MLTC) as it is more accepted and understood by patients and the public. [12]

Causes

Risk factors

A range of biological, psychological, behavioural, socioeconomic and environmental factors affect the likelihood of having multimorbidity. How these risk factors interact to trigger multiple long-term conditions is complex and still not fully understood. [1]

One risk factor of multimorbidity in young people is being born premature. [13] [14] Lifestyle factors that may increase the risk of multiple long-term conditions include obesity, poor diet, poor sleep, smoking, air pollution, alcohol; and lifestyles factors that may reduce the risk of MLTC includes eating a healthy diet, physical activity, and strong social networks. [1] [15]

Lower socioeconomic status, measured by a combination of education, occupation and literacy indicators, seems to increase the risk of developing multimorbidity. [16] For instance, based on the Whitehall II Study, people in lower employment positions seem to have a 66% higher risk of developing multiple long-term conditions than people in higher positions. However, socioeconomic status does not appear to influence the risk of dying after the onset of multiple long-term conditions. [16] Another study showed an increase of almost 50% in the odds of multimorbidity occurring in those with the least wealth compared to those with the most wealth. [17] Therefore, reducing socioeconomic inequalities by improving working and living conditions and education to everyone is important to reduce the burden of multiple long-term conditions on population health. [16]

Diagnosis and impact

Multimorbidity is associated with reduced quality of life [18] and increased risk of death. [19] The risk of death is positively associated with individuals with greater number of chronic conditions and reversely associated with socioeconomic status. [19] People with multiple long-term conditions may have a four-fold increase in the risk of death in comparison with people without MLTC irrespective of their socioeconomic status. [16]

In some cases, specific combinations of diseases are associated with higher mortality. [20] For example, people with long-term conditions affecting the heart, lung, and urinary systems have strong effects on mortality. [20]

There are many additional issues associated with living with multiple long term conditions. One study from the US found that having more than 3 conditions significantly increased the chance of reduced quality of life and physical functioning. The researchers called for the holistic treatment of multimorbidities due to the complexities of multiple long-term conditions. [21]

Due to the higher prevalence of multimorbidity (55 - 98%), [2] a new concept of "complex multimorbidity (CMM)" has been proposed [22] CMM differs from the definition of conventional multimorbidity in that CMM is defined by the number of body systems affected by the diseases rather than the number of diseases. CMM is associated is mortality and long-term care needs in older adults. [23] [24] [25]

Mental health

Physical and mental health conditions can adversely impact the other through a number of pathways, and have significant impact on health and wellbeing. [26] For people whose long-term conditions include severe mental illness, the lifespan can be 10–20 years less than the general population. [27] For them, addressing the underlying risk factors for physical health problems is critical to good outcomes. [26]

There is considerable evidence that having multiple long-term physical conditions can lead to the development of both depression and anxiety. [28] There are many factors which might explain why physical multi-morbidity affects mental health including chronic pain, [29] frailty, [30] [31] symptom burden, [32] functional impairment, [33] reduced quality of life, [18] increased levels of inflammation, [34] and polypharmacy. [35] Evidence from large population studies from the United Kingdom and China suggests that specific combinations of physical conditions increase the risk of developing depression and anxiety more than others, such as co-occurring respiratory disorders and co-occurring painful and gastrointestinal disorders. [36] [37] There has been a scarcity of economic evaluations concerning interventions for managing individuals with mental-physical multimorbidity, including depression. A recent systematic review identified four intervention types (collaborative care, self-management, telephone-based, and antidepressant treatment)) that were assessed for cost-effectiveness in high-income countries. [38] However, such evaluations are currently lacking in low-income and middle-income countries.[ citation needed ]

Strategies to prevent the onset of depression or depressive episodes in people with long-term physical conditions include psychological interventions and pharmacological interventions, however the long-term effectiveness and benefits of these approaches is very uncertain. [39]

Healthcare

People with multimorbidity face many challenges because of the way health systems are organised. Most health systems are designed to cater for people with a single chronic condition. [40] Some of the difficulties experienced by people with multiple long-term conditions include: poor coordination of medical care, managing multiple medications (polypharmacy), high costs associated with treatment, [41] increases in their time spent managing illness, [42] difficulty managing multiple illness management regimes, [43] and aggravation of one condition by symptoms or treatment of another. [44]

There is growing recognition that living with multiple long-term conditions leads to complex and challenging burdens for people living with MLTC themselves but also health care professionals working in the health system looking after those with long-term conditions. Living with multiple-long term conditions can be burdensome in terms of managing the illness, particularly if the diagnoses results in polypharmacy (taking multiple medicines). [1]

Medication management

Older people and their family carers frequently find medication management a burden. This burden fluctuates and is often is hidden from health and social care practitioners. [45] [46] For example, the burden, on the family carer, may increase if the older person is suffering from confusion or dementia. [47] In general there are five burdens that make managing medicines challenging for older people: when the purpose of reviewing medicines is not clear to the person; when a lack of information prevents the person contributing to decisions about their health; when people with MLTC don't see the same health care professional consistently; when people are seen by lots of different professionals working across different services; and when the health service does not recognise the experiences of people living with MLTC. To help older people and their family carers experiencing medication-related burden, medical professionals can consider this burden when changing or amending a medication. [48] [45]

Multimorbidity often results in taking 5 or more medicines (polypharmacy) which can represent a burden and might come with potential harm. When the medications are not effective enough or the risks outweigh the benefits, stopping medicines (deprescribing) might be necessary. In people with multiple long-term conditions and polypharmacy this represents a complex challenge as clinical guidelines are usually developed for single conditions. In these cases tools and guidelines like the Beers Criteria and STOPP/START could be used safely by clinicians but not all patients might benefit from stopping their medication. Clarity about how much clinicians can do beyond the guidelines and the responsibility they need to take could help them prescribing and deprescribing for complex cases. Further factors that can help clinicians tailor their decisions to the individual are: access to detailed data on the people in their care (including their backgrounds and personal medical goals), discussing plans to stop a medicine already when it is first prescribed, and a good relationship that involves mutual trust and regular discussions on progress. Furthermore, longer appointments for prescribing and deprescribing would allow time explain the process of deprescribing, explore related concerns, and support making the right decisions. [49] [50]

Prevention

There are well-evidenced prevention strategies for many of the component diseases of multiple condition clusters. For example:

An increased understanding of which conditions most commonly cluster, along with  their underlying risk factors, would help prioritise strategies for early diagnosis, screening and prevention. [1]

Epidemiology

Multimorbidity is common in older adults, estimated to affect over half of those aged 65 and over. This increased prevalence has been explained by older adults' "longer exposure and increased vulnerability to risk factors for chronic health problems". [2]

The prevalence of multimorbidity has been increasing in recent decades. [52] [53] [54] The high prevalence of multimorbidity has led to some describing it as "The most common chronic condition". [55] Multimorbidity is also more common among people from lower socioeconomic statuses. [2] [56] [57] Multimorbidity is a significant issue in low‐ and middle‐income countries, although prevalence is not as high as in high income countries. [58]

As a global health issue and in the demographic transition

Number of conditions ever recorded per individual (from 308 health conditions), stratified by age, sex, and ethnicity Number of conditions ever recorded per individual (from 308 health conditions), stratified by age, sex, and ethnicity.jpg
Number of conditions ever recorded per individual (from 308 health conditions), stratified by age, sex, and ethnicity
Comparison of comorbidities for primary breast cancer by ethnicity (A), and asthma by sex (B) Comparison of comorbidities for primary breast cancer by ethnicity (A), and asthma by sex (B).jpg
Comparison of comorbidities for primary breast cancer by ethnicity (A), and asthma by sex (B)
This section is an excerpt from Global health § Multimorbidity, age-related diseases and aging.[ edit ]

Multimorbidity is "a growing public health problem worldwide", "likely driven by the ageing population but also by factors such as high body-mass index, urbanisation, and the growing burden of NCDs (such as type 2 diabetes) and tuberculosis in low- and middle-income countries (LMICs)". [59] [60] [61] Around the world, many people do not die from one isolated condition but from a multitude of factors and conditions. A study suggested there is a paucity of multimorbidity and comorbidity data globally and mapped comorbidity patterns. [62]

With aging populations, there is a rise of age-related diseases which puts major burdens on healthcare systems as well as contemporary economies or contemporary economics and their appendant societal systems. Healthspan extension and anti-aging research seek to extend the span of health in the old as well as slow aging or its negative impacts such as physical and mental decline. Modern anti-senescent and regenerative technology with augmented decision making could help "responsibly bridge the healthspan-lifespan gap for a future of equitable global wellbeing". [63] Aging is "the most prevalent risk factor for chronic disease, frailty and disability, and it is estimated that there will be over 2 billion persons age > 60 by the year 2050", making it a large global health challenge that demands substantial (and well-orchestrated or efficient) efforts, including interventions that alter and target the inborn aging process. [64]

Health inequalities

The likelihood of having multiple long-term conditions is increased by socioeconomic inequalities. Certain groups of disadvantaged or discriminated people are more likely to struggle with earlier and more severe multimorbidity. [65] Multimorbidity is also associated with factors that are related to socioeconomic disadvantage such as food insecurity, [66] low level of education, living in deprived areas and having unhealthy lifestyles. [67]

There are multiple theories on how socioeconomic inequality leads to multimorbidity but so far there is a lack of scientific evidence about the exact mechanism. Some of the potential links between the two are health-related behaviours (smoking, drinking, diet), lack of access to financial resources and housing, and the psychological response to living in difficult circumstances. Knowing the exact pathway would allow designing effective interventions that prevent or mitigate inequalities in multimorbidity. [65] [68]

Deprivation and poverty

Living in poverty or deprived areas is associated with higher rates of multimorbidity. [65] [69] Those with the lowest income have a 4 times higher chance of having multiple long-term conditions than those with the highest income. [70] Self-management is vital in coping with multimorbidity but people living in deprivation struggle more with managing their conditions. Self-management becomes more challenging due to financial barriers, health literacy (difficulties with understanding health information) and the combined weight of multimorbidity and deprivation. [71]

Research shows that in Scotland residents of deprived areas are affected by multiple long-term conditions 10 to 15 years earlier than people living in affluent neighborhoods. They also have a higher chance that their long-term conditions include mental health disorders. [72] In England, according to research, people from deprived neighborhoods had complex multimorbidity (3 or more conditions) 7 years earlier than the least deprived. [73] People living in deprived areas also have a higher risk of dying because of multimorbidity. [74]

Ethnicity and sexual orientation

Ethnic inequalities also affect who acquires multimorbidity. [75] [76] [77] In the United Kingdom, Indian, Pakistani, Bangladeshi, Black African, Black Caribbean people and those who identify as Black other, other Asian, and mixed ethnicity have a higher risk of developing multiple long-term conditions. In England, people from Pakistani and Bangladeshi backgrounds have the highest multimorbidity rates and they are twice as likely than people from the Chinese minority to have multimorbidity. [65] [78] Pakistani, Black African, Black Caribbean and other black ethnic groups in England are also significantly more likely to die due to having multiple long-term conditions. [79]

Belonging to a sexual minority also means being disproportionately affected by multimorbidity, especially mental health conditions. [80] [81] [82]

Research directions

Research funders in the UK, including the Medical Research Council (MRC), the Wellcome Trust and the National Institute for Health and Care Research (NIHR) have published the "Cross-funder multimorbidity research framework" which sets out a vision for the research agenda of multiple long-term conditions. The framework aims to drive advances in the understanding of multiple long-term conditions and promote a change in research culture to tackle multimorbidity. [83] [84] The NIHR also published its own strategic framework regarding MLTC which aligns with the cross-funder framework. [12]

As rehabilitation usually focuses on a single disease people with multiple long-term conditions are often excluded or not all their conditions are treated during rehabilitation. Researchers are looking for new models of rehabilitation that could be applied to people with multimorbidity. [85] [86] For example the PERFORM (Personalised Exercise-Rehabilitation For people with Multiple long-term conditions) research group in the UK is developing and evaluating an exercise-based rehabilitation intervention that can be personalised for people with multiple long-term conditions. [87] The MOBILIZE group in Denmark are currently undertaking a randomised controlled trial of a rehabilitation intervention for people with multimorbidity co-developed with people with long-term conditions and clinicians. [88]

Related Research Articles

<span class="mw-page-title-main">Major depressive disorder</span> Mental disorder involving persistent low mood, low self-esteem, and loss of interest

Major depressive disorder (MDD), also known as clinical depression, is a mental disorder characterized by at least two weeks of pervasive low mood, low self-esteem, and loss of interest or pleasure in normally enjoyable activities. Introduced by a group of US clinicians in the mid-1970s, the term was adopted by the American Psychiatric Association for this symptom cluster under mood disorders in the 1980 version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III), and has become widely used since.

<span class="mw-page-title-main">Chronic pain</span> Pain that lasts longer than three months

Chronic pain or chronic pain syndrome is a type of pain that is also known by other titles such as gradual burning pain, electrical pain, throbbing pain, and nauseating pain. This type of pain is sometimes confused with acute pain and can last from three months to several years; Various diagnostic manuals such as DSM-5 and ICD-11 have proposed several definitions of chronic pain, but the accepted definition is that it is "pain that lasts longer than the expected period of recovery."

In medicine, comorbidity—from Latin morbus ("sickness"), co ("together"), -ity —is the presence of one or more additional conditions often co-occurring with a primary condition. Comorbidity describes the effect of all other conditions an individual patient might have other than the primary condition of interest, and can be physiological or psychological. In the context of mental health, comorbidity often refers to disorders that are often coexistent with each other, such as depression and anxiety disorders. The concept of multimorbidity is related to comorbidity but presents a different meaning and approach.

<span class="mw-page-title-main">Cardiovascular disease</span> Class of diseases that involve the heart or blood vessels

Cardiovascular disease (CVD) is any disease involving the heart or blood vessels. CVDs constitute a class of diseases that includes: coronary artery diseases, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, arrhythmia, congenital heart disease, valvular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease, and venous thrombosis.

<span class="mw-page-title-main">Polypharmacy</span> Use of five or more medications daily

Polypharmacy (polypragmasia) is an umbrella term to describe the simultaneous use of multiple medicines by a patient for their conditions. The term polypharmacy is often defined as regularly taking five or more medicines but there is no standard definition and the term has also been used in the context of when a person is prescribed 2 or more medications at the same time. Polypharmacy may be the consequence of having multiple long-term conditions, also known as multimorbidity and is more common in people who are older. In some cases, an excessive number of medications at the same time is worrisome, especially for people who are older with many chronic health conditions, because this increases the risk of an adverse event in that population. In many cases, polypharmacy cannot be avoided, but 'appropriate polypharmacy' practices are encouraged to decrease the risk of adverse effects. Appropriate polypharmacy is defined as the practice of prescribing for a person who has multiple conditions or complex health needs by ensuring that medications prescribed are optimized and follow 'best evidence' practices.

<span class="mw-page-title-main">Global health</span> Health of populations in a global context

Global health is the health of the populations in the worldwide context; it has been defined as "the area of study, research, and practice that places a priority on improving health and achieving equity in health for all people worldwide". Problems that transcend national borders or have a global political and economic impact are often emphasized. Thus, global health is about worldwide health improvement, reduction of disparities, and protection against global threats that disregard national borders, including the most common causes of human death and years of life lost from a global perspective.

A chronic condition is a health condition or disease that is persistent or otherwise long-lasting in its effects or a disease that comes with time. The term chronic is often applied when the course of the disease lasts for more than three months. Common chronic diseases include diabetes, functional gastrointestinal disorder, eczema, arthritis, asthma, chronic obstructive pulmonary disease, autoimmune diseases, genetic disorders and some viral diseases such as hepatitis C and acquired immunodeficiency syndrome. An illness which is lifelong because it ends in death is a terminal illness. It is possible and not unexpected for an illness to change in definition from terminal to chronic. Diabetes and HIV for example were once terminal yet are now considered chronic due to the availability of insulin for diabetics and daily drug treatment for individuals with HIV which allow these individuals to live while managing symptoms.

<span class="mw-page-title-main">Allostatic load</span> Wear and tear on the body due to stress

Allostatic load is "the wear and tear on the body" which accumulates as an individual is exposed to repeated or chronic stress. The term was coined by Bruce McEwen and Eliot Stellar in 1993. It represents the physiological consequences of chronic exposure to fluctuating or heightened neural or neuroendocrine response which results from repeated or prolonged chronic stress.

Chronic care management encompasses the oversight and education activities conducted by health care professionals to help patients with chronic diseases and health conditions such as diabetes, high blood pressure, systemic lupus erythematosus, multiple sclerosis, and sleep apnea learn to understand their condition and live successfully with it. This term is equivalent to disease management for chronic conditions. The work involves motivating patients to persist in necessary therapies and interventions and helping them to achieve an ongoing, reasonable quality of life.

<span class="mw-page-title-main">Preventable causes of death</span> Causes of death that could have been avoided

Preventable causes of death are causes of death related to risk factors which could have been avoided. The World Health Organization has traditionally classified death according to the primary type of disease or injury. However, causes of death may also be classified in terms of preventable risk factors—such as smoking, unhealthy diet, sexual behavior, and reckless driving—which contribute to a number of different diseases. Such risk factors are usually not recorded directly on death certificates, although they are acknowledged in medical reports.

<span class="mw-page-title-main">Obesity-associated morbidity</span> Medical condition

Obesity is a risk factor for many chronic physical and mental illnesses.

<span class="mw-page-title-main">Doctor's visit</span>

A doctor's visit, also known as a physician office visit or a consultation, or a ward round in an inpatient care context, is a meeting between a patient with a physician to get health advice or treatment plan for a symptom or condition, most often at a professional health facility such as a doctor's office, clinic or hospital. According to a survey in the United States, a physician typically sees between 50 and 100 patients per week, but it may vary with medical specialty, but differs only little by community size such as metropolitan versus rural areas.

<span class="mw-page-title-main">Myalgic encephalomyelitis/chronic fatigue syndrome</span> Medical condition

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating long-term medical condition. People with ME/CFS experience lengthy flare-ups of the illness following relatively minor physical or mental activity. This is known as post-exertional malaise (PEM) and is the hallmark symptom of the illness. Other core symptoms are a greatly reduced ability to do tasks that were previously routine, severe fatigue, and sleep disturbances. The baseline fatigue in ME/CFS does not improve much with rest. Orthostatic intolerance, memory and concentration problems, and chronic pain are common. About a quarter of people with ME/CFS are severely affected and unable to leave their bed or home.

<span class="mw-page-title-main">Chronic obstructive pulmonary disease</span> Lung disease involving long-term poor airflow

Chronic obstructive pulmonary disease (COPD) is a type of progressive lung disease characterized by long-term respiratory symptoms and airflow limitation. The main symptoms of COPD include shortness of breath and a cough, which may or may not produce mucus. COPD progressively worsens, with everyday activities such as walking or dressing becoming difficult. While COPD is incurable, it is preventable and treatable. The two most common types of COPD are emphysema and chronic bronchitis and have been the two classic COPD phenotypes. However, this basic dogma has been challenged as varying degrees of co-existing emphysema, chronic bronchitis, and potentially significant vascular diseases have all been acknowledged in those with COPD, giving rise to the classification of other phenotypes or subtypes. Emphysema is defined as enlarged airspaces (alveoli) whose walls have broken down resulting in permanent damage to the lung tissue. Chronic bronchitis is defined as a productive cough that is present for at least three months each year for two years. Both of these conditions can exist without airflow limitation when they are not classed as COPD. Emphysema is just one of the structural abnormalities that can limit airflow and can exist without airflow limitation in a significant number of people. Chronic bronchitis does not always result in airflow limitation but in young adults with chronic bronchitis who smoke, the risk of developing COPD is high. Many definitions of COPD in the past included emphysema and chronic bronchitis, but these have never been included in GOLD report definitions. Emphysema and chronic bronchitis remain the predominant phenotypes of COPD but there is often overlap between them and a number of other phenotypes have also been described. COPD and asthma may coexist and converge in some individuals. COPD is associated with low-grade systemic inflammation.

Childhood chronic illness refers to conditions in pediatric patients that are usually prolonged in duration, do not resolve on their own, and are associated with impairment or disability. The duration required for an illness to be defined as chronic is generally greater than 12 months, but this can vary, and some organizations define it by limitation of function rather than a length of time. Regardless of the exact length of duration, these types of conditions are different than acute, or short-lived, illnesses which resolve or can be cured. There are many definitions for what counts as a chronic condition. However, children with chronic illnesses will typically experience at least one of the following: limitation of functions relative to their age, disfigurement, dependency on medical technologies or medications, increased medical attention, and a need for modified educational arrangements.

<span class="mw-page-title-main">Deprescribing</span> Process to taper or stop medications

Deprescribing is a process to taper or stop medications with the intention to achieve improved health outcomes by reducing exposure to medications that are potentially either harmful or no longer required. Deprescribing is important to consider with changing health and care goals over time, as well as polypharmacy and adverse effects. Deprescribing can improve adherence, cost, and health outcomes but may have adverse drug withdrawal effects. More specifically, deprescribing is the planned and supervised process of intentionally stopping a medication or reducing its dose to improve the person's health or reduce the risk of adverse side effects. Deprescribing is usually done because the drug may be causing harm, may no longer be helping the patient, or may be inappropriate for the individual patient's current situation. Deprescribing can help correct polypharmacy and prescription cascade.

The taxonomy of the burden of treatment is a visualization created for health care professionals to better comprehend the obstacles that interfere with a patient's health care plan. It was created as a result of a worldwide, qualitative-based study that asked adults with chronic conditions to list the personal, environmental, and financial barriers that burden a patient. The purpose of this visualization is to help health care providers develop personalized management strategies that the patient can follow through a narrative paradigm. The goal is to target interventions, achieve an interpersonal doctor-patient relationship, and improve health outcomes.

Long COVID or long-haul COVID is a group of health problems persisting or developing after an initial period of COVID-19 infection. Symptoms can last weeks, months or years and are often debilitating. The World Health Organization defines long COVID as starting three months after the initial COVID-19 infection, but other agencies define it as starting at four weeks after the initial infection.

In medicine, the Charlson Comorbidity Index (CCI) predicts the mortality for a patient who may have a range of concurrent conditions (comorbidities), such as heart disease, AIDS, or cancer. A score of zero means that no comorbidities were found; the higher the score, the higher the predicted mortality rate is. For a physician, this score is helpful in deciding how aggressively to treat a condition.

References

  1. 1 2 3 4 5 6 7 "Multiple long-term conditions (multimorbidity): making sense of the evidence". NIHR Evidence. National Institute for Health and Care Research. 30 March 2021. doi:10.3310/collection_45881. S2CID   243406561.
  2. 1 2 3 4 5 Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. (September 2011). "Aging with multimorbidity: a systematic review of the literature". Ageing Research Reviews. 10 (4): 430–439. doi:10.1016/j.arr.2011.03.003. PMID   21402176. S2CID   40912813.
  3. ↑ Nguyen H, Manolova G, Daskalopoulou C, Vitoratou S, Prince M, Prina AM (1 January 2019). "Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies". Journal of Comorbidity. 9: 2235042X19870934. doi:10.1177/2235042X19870934. PMC   6710708 . PMID   31489279.
  4. ↑ Johnston MC, Crilly M, Black C, Prescott GJ, Mercer SW (February 2019). "Defining and measuring multimorbidity: a systematic review of systematic reviews". European Journal of Public Health. 29 (1): 182–189. doi: 10.1093/eurpub/cky098 . hdl: 20.500.11820/fdedbe90-e4ec-43b8-bb78-a0f75efe6305 . PMID   29878097.
  5. ↑ Xu X, Mishra GD, Jones M (August 2017). "Evidence on multimorbidity from definition to intervention: An overview of systematic reviews" (PDF). Ageing Research Reviews. 37: 53–68. doi:10.1016/j.arr.2017.05.003. PMID   28511964. S2CID   3665446.
  6. 1 2 3 4 Multimorbidity: a priority for global health research. Academy of Medical Sciences. 2018.
  7. ↑ Nicholson K, Makovski TT, Griffith LE, Raina P, Stranges S, van den Akker M (January 2019). "Multimorbidity and comorbidity revisited: refining the concepts for international health research". Journal of Clinical Epidemiology. 105: 142–146. doi:10.1016/j.jclinepi.2018.09.008. PMID   30253215. S2CID   52825086.
  8. 1 2 Harrison C, Fortin M, van den Akker M, Mair F, Calderon-Larranaga A, Boland F, et al. (1 January 2021). "Comorbidity versus multimorbidity: Why it matters". Journal of Comorbidity. 11: 2633556521993993. doi:10.1177/2633556521993993. PMC   7930649 . PMID   33718251.
  9. ↑ Chua YP, Xie Y, Lee PS, Lee ES (February 2021). "Definitions and Prevalence of Multimorbidity in Large Database Studies: A Scoping Review". International Journal of Environmental Research and Public Health. 18 (4): 1673. doi: 10.3390/ijerph18041673 . PMC   7916224 . PMID   33572441.
  10. ↑ "Multimorbidity: clinical assessment and management - Recommendations". National Institute for Health and Care Excellence (NICE). 21 September 2016. Retrieved 27 May 2022.
  11. ↑ Almirall J, Fortin M (January 2013). "The coexistence of terms to describe the presence of multiple concurrent diseases". Journal of Comorbidity. 3 (1): 4–9. doi:10.15256/joc.2013.3.22. PMC   5636023 . PMID   29090140.
  12. 1 2 "NIHR Strategic Framework for Multiple Long-Term Conditions (Multimorbidity) MLTC-M Research". National Institute for Health and Care Research (NIHR). Retrieved 27 June 2022.
  13. ↑ Heikkilä, Katriina; Pulakka, Anna; Metsälä, Johanna; Alenius, Suvi; Hovi, Petteri; Gissler, Mika; Sandin, Sven; Kajantie, Eero (31 December 2021). "Preterm birth and the risk of chronic disease multimorbidity in adolescence and early adulthood: A population-based cohort study". PLOS ONE. 16 (12): e0261952. Bibcode:2021PLoSO..1661952H. doi: 10.1371/journal.pone.0261952 . ISSN   1932-6203. PMC   8719774 . PMID   34972182.
  14. ↑ Heikkilä, Katriina; Metsälä, Johanna; Pulakka, Anna; Nilsen, Sara Marie; Kivimäki, Mika; Risnes, Kari; Kajantie, Eero (September 2023). "Preterm birth and the risk of multimorbidity in adolescence: a multiregister-based cohort study". The Lancet Public Health. 8 (9): e680–e690. doi:10.1016/S2468-2667(23)00145-7. hdl: 11250/3103131 . PMID   37633677. S2CID   261187781.
  15. ↑ Sindi S, Pérez LM, Vetrano DL, Triolo F, Kåreholt I, Sjöberg L, et al. (December 2020). "Sleep disturbances and the speed of multimorbidity development in old age: results from a longitudinal population-based study". BMC Medicine. 18 (1): 382. doi: 10.1186/s12916-020-01846-w . PMC   7720467 . PMID   33280611.
  16. 1 2 3 4 Dugravot A, Fayosse A, Dumurgier J, Bouillon K, Rayana TB, Schnitzler A, et al. (January 2020). "Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study". The Lancet. Public Health. 5 (1): e42–e50. doi:10.1016/S2468-2667(19)30226-9. PMC   7098476 . PMID   31837974.
  17. ↑ Singer L, Green M, Rowe F, Ben-Shlomo Y, Morrissey K (August 2019). "Social determinants of multimorbidity and multiple functional limitations among the ageing population of England, 2002-2015". SSM - Population Health. 8: 100413. doi:10.1016/j.ssmph.2019.100413. PMC   6551564 . PMID   31194123.
  18. 1 2 Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M (August 2019). "Multimorbidity and quality of life: Systematic literature review and meta-analysis" (PDF). Ageing Research Reviews. 53: 100903. doi:10.1016/j.arr.2019.04.005. PMID   31048032. S2CID   139101266.
  19. 1 2 Nunes BP, Flores TR, Mielke GI, Thumé E, Facchini LA (November 2016). "Multimorbidity and mortality in older adults: A systematic review and meta-analysis". Archives of Gerontology and Geriatrics. 67: 130–138. doi:10.1016/j.archger.2016.07.008. PMID   27500661.
  20. 1 2 Gijsen R, Hoeymans N, Schellevis FG, Ruwaard D, Satariano WA, van den Bos GA (July 2001). "Causes and consequences of comorbidity: a review". Journal of Clinical Epidemiology. 54 (7): 661–674. doi:10.1016/s0895-4356(00)00363-2. PMID   11438406.
  21. ↑ Williams JS, Egede LE (July 2016). "The Association Between Multimorbidity and Quality of Life, Health Status and Functional Disability". The American Journal of the Medical Sciences. 352 (1): 45–52. doi:10.1016/j.amjms.2016.03.004. PMID   27432034. S2CID   3455192.
  22. ↑ Harrison C, Britt H, Miller G, Henderson J (July 2014). "Examining different measures of multimorbidity, using a large prospective cross-sectional study in Australian general practice". BMJ Open. 4 (7): e004694. doi:10.1136/bmjopen-2013-004694. PMC   4120329 . PMID   25015470.
  23. ↑ Storeng SH, Vinjerui KH, Sund ER, Krokstad S (January 2020). "Associations between complex multimorbidity, activities of daily living and mortality among older Norwegians. A prospective cohort study: the HUNT Study, Norway". BMC Geriatrics. 20 (1): 21. doi: 10.1186/s12877-020-1425-3 . PMC   6974981 . PMID   31964341.
  24. ↑ Kato D, Kawachi I, Saito J, Kondo N (August 2021). "Complex multimorbidity and mortality in Japan: a prospective propensity-matched cohort study". BMJ Open. 11 (8): e046749. doi:10.1136/bmjopen-2020-046749. PMC   8330573 . PMID   34341044.
  25. ↑ Kato D, Kawachi I, Saito J, Kondo N (October 2021). "Complex Multimorbidity and Incidence of Long-Term Care Needs in Japan: A Prospective Cohort Study". International Journal of Environmental Research and Public Health. 18 (19): 10523. doi: 10.3390/ijerph181910523 . PMC   8508235 . PMID   34639825.
  26. 1 2 Firth J, Siddiqi N, Koyanagi A, Siskind D, Rosenbaum S, Galletly C, et al. (August 2019). "The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness". The Lancet. Psychiatry. 6 (8): 675–712. doi:10.1016/S2215-0366(19)30132-4. hdl: 10072/391717 . PMID   31324560. S2CID   198134221.
  27. ↑ World Health Organization, issuing body (14 August 2018). Management of physical health conditions in adults with severe mental disorders : WHO guidelines. World Health Organization. ISBN   978-92-4-155038-3. OCLC   1089879045.
  28. ↑ Triolo F, Harber-Aschan L, Belvederi Murri M, Calderón-Larrañaga A, Vetrano DL, Sjöberg L, et al. (December 2020). "The complex interplay between depression and multimorbidity in late life: risks and pathways". Mechanisms of Ageing and Development. 192: 111383. doi: 10.1016/j.mad.2020.111383 . hdl: 11392/2437730 . PMID   33045250. S2CID   222233540.
  29. ↑ Sharpe L, McDonald S, Correia H, Raue PJ, Meade T, Nicholas M, Arean P (May 2017). "Pain severity predicts depressive symptoms over and above individual illnesses and multimorbidity in older adults". BMC Psychiatry. 17 (1): 166. doi: 10.1186/s12888-017-1334-y . PMC   5418685 . PMID   28472936.
  30. ↑ Vetrano DL, Palmer K, Marengoni A, Marzetti E, Lattanzio F, Roller-Wirnsberger R, et al. (April 2019). "Frailty and Multimorbidity: A Systematic Review and Meta-analysis". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 74 (5): 659–666. doi: 10.1093/gerona/gly110 . PMID   29726918.
  31. ↑ Soysal P, Veronese N, Thompson T, Kahl KG, Fernandes BS, Prina AM, et al. (July 2017). "Relationship between depression and frailty in older adults: A systematic review and meta-analysis". Ageing Research Reviews. 36: 78–87. doi:10.1016/j.arr.2017.03.005. PMID   28366616. S2CID   205668529.
  32. ↑ Katon W, Lin EH, Kroenke K (1 March 2007). "The association of depression and anxiety with medical symptom burden in patients with chronic medical illness". General Hospital Psychiatry. 29 (2): 147–155. doi:10.1016/j.genhosppsych.2006.11.005. PMID   17336664.
  33. ↑ Calderón-Larrañaga A, Vetrano DL, Ferrucci L, Mercer SW, Marengoni A, Onder G, et al. (March 2019). "Multimorbidity and functional impairment-bidirectional interplay, synergistic effects and common pathways". Journal of Internal Medicine. 285 (3): 255–271. doi:10.1111/joim.12843. PMC   6446236 . PMID   30357990.
  34. ↑ Miller AH, Raison CL (January 2016). "The role of inflammation in depression: from evolutionary imperative to modern treatment target". Nature Reviews. Immunology. 16 (1): 22–34. doi:10.1038/nri.2015.5. PMC   5542678 . PMID   26711676.
  35. ↑ Holvast F, van Hattem BA, Sinnige J, Schellevis F, Taxis K, Burger H, Verhaak PF (September 2017). "Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study". Family Practice. 34 (5): 539–545. doi: 10.1093/fampra/cmx018 . PMID   28369380.
  36. ↑ Yao SS, Cao GY, Han L, Huang ZT, Chen ZS, Su HX, et al. (September 2020). "Associations Between Somatic Multimorbidity Patterns and Depression in a Longitudinal Cohort of Middle-Aged and Older Chinese". Journal of the American Medical Directors Association. 21 (9): 1282–1287.e2. doi:10.1016/j.jamda.2019.11.028. PMID   31928934. S2CID   210191651.
  37. ↑ Ronaldson A, Arias de la Torre J, Prina M, Armstrong D, Das-Munshi J, Hatch S, et al. (September 2021). "Associations between physical multimorbidity patterns and common mental health disorders in middle-aged adults: A prospective analysis using data from the UK Biobank". The Lancet Regional Health. Europe. 8: 100149. doi:10.1016/j.lanepe.2021.100149. PMC   8447568 . PMID   34557851.
  38. ↑ Banstola A, Pokhrel S, Hayhoe B, Nicholls D, Harris M, Anokye N (February 2023). "Economic evaluations of interventional opportunities for the management of mental-physical multimorbidity: a systematic review". BMJ Open. 13 (2): e069270. doi:10.1136/bmjopen-2022-069270. PMC   9980364 . PMID   36854591.
  39. ↑ Kampling H, Baumeister H, Bengel J, Mittag O (March 2021). "Prevention of depression in adults with long-term physical conditions". The Cochrane Database of Systematic Reviews. 2021 (3): CD011246. doi:10.1002/14651858.CD011246.pub2. PMC   8092431 . PMID   33667319.
  40. ↑ Salisbury C (July 2012). "Multimorbidity: redesigning health care for people who use it". Lancet. 380 (9836): 7–9. doi:10.1016/S0140-6736(12)60482-6. PMID   22579042. S2CID   12325320.
  41. ↑ Wang L, Si L, Cocker F, Palmer AJ, Sanderson K (February 2018). "A Systematic Review of Cost-of-Illness Studies of Multimorbidity" (PDF). Applied Health Economics and Health Policy. 16 (1): 15–29. doi:10.1007/s40258-017-0346-6. PMID   28856585. S2CID   21008606.
  42. ↑ Jowsey T, McRae IS, Valderas JM, Dugdale P, Phillips R, Bunton R, et al. (2013). "Time's up. descriptive epidemiology of multi-morbidity and time spent on health related activity by older Australians: a time use survey". PLOS ONE. 8 (4): e59379. Bibcode:2013PLoSO...859379J. doi: 10.1371/journal.pone.0059379 . PMC   3613388 . PMID   23560046.
  43. ↑ Jowsey T, Dennis S, Yen L, Mofizul Islam M, Parkinson A, Dawda P (July 2016). "Time to manage: patient strategies for coping with an absence of care coordination and continuity". Sociology of Health & Illness. 38 (6): 854–873. doi: 10.1111/1467-9566.12404 . PMID   26871716.
  44. ↑ Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS (2003). "Descriptions of barriers to self-care by persons with comorbid chronic diseases". Annals of Family Medicine. 1 (1): 15–21. doi:10.1370/afm.4. PMC   1466563 . PMID   15043175.
  45. 1 2 Maidment, Ian D.; Lawson, Sally; Wong, Geoff; Booth, Andrew; Watson, Anne; McKeown, Jane; Zaman, Hadar; Mullan, Judy; Bailey, Sylvia (June 2020). "Medication management in older people: the MEMORABLE realist synthesis". Health Services and Delivery Research. 8 (26): 1–128. doi: 10.3310/hsdr08260 . PMID   32579319. S2CID   225671789.
  46. ↑ Lawson S, Mullan J, Wong G, Zaman H, Booth A, Watson A, Maidment I (July 2022). "Family carers' experiences of managing older relative's medications: Insights from the MEMORABLE study" (PDF). Patient Education and Counseling. 105 (7): 2573–2580. doi:10.1016/j.pec.2021.12.017. PMID   35016779. S2CID   245620865.
  47. ↑ Maidment ID, Aston L, Moutela T, Fox CG, Hilton A (October 2017). "A qualitative study exploring medication management in people with dementia living in the community and the potential role of the community pharmacist". Health Expectations. 20 (5): 929–942. doi:10.1111/hex.12534. PMC   5600213 . PMID   28105781.
  48. ↑ "Managing medication: older people and their families need support to deal with the hidden burden of medication". NIHR Evidence (Plain English summary). 24 November 2020. doi:10.3310/alert_42757. S2CID   240496292.
  49. ↑ "How to reduce medications for people with multiple long-term conditions". NIHR Evidence. 18 May 2023. doi:10.3310/nihrevidence_57904. S2CID   258801327.
  50. ↑ Reeve J, Maden M, Hill R, Turk A, Mahtani K, Wong G, et al. (July 2022). "Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis". Health Technology Assessment. 26 (32): 1–148. doi:10.3310/AAFO2475. PMC   9376985 . PMID   35894932.
  51. ↑ Head A, Fleming K, Kypridemos C, Pearson-Stuttard J, O'Flaherty M (March 2021). "Multimorbidity: the case for prevention". Journal of Epidemiology and Community Health. 75 (3): 242–244. doi:10.1136/jech-2020-214301. PMC   7892394 . PMID   33020144.
  52. ↑ King DE, Xiang J, Pilkerton CS (2018). "Multimorbidity Trends in United States Adults, 1988-2014". Journal of the American Board of Family Medicine. 31 (4): 503–513. doi:10.3122/jabfm.2018.04.180008. PMC   6368177 . PMID   29986975.
  53. ↑ Pefoyo AJ, Bronskill SE, Gruneir A, Calzavara A, Thavorn K, Petrosyan Y, et al. (April 2015). "The increasing burden and complexity of multimorbidity". BMC Public Health. 15: 415. doi: 10.1186/s12889-015-1733-2 . PMC   4415224 . PMID   25903064.
  54. ↑ Uijen AA, van de Lisdonk EH (2008). "Multimorbidity in primary care: prevalence and trend over the last 20 years". The European Journal of General Practice. 14 (sup1): 28–32. doi: 10.1080/13814780802436093 . hdl: 11250/2487933 . PMID   18949641. S2CID   34601052.
  55. ↑ Tinetti ME, Fried TR, Boyd CM (June 2012). "Designing health care for the most common chronic condition--multimorbidity". JAMA. 307 (23): 2493–2494. doi:10.1001/jama.2012.5265. PMC   4083627 . PMID   22797447.
  56. ↑ Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B (July 2012). "Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study". Lancet. 380 (9836): 37–43. doi: 10.1016/S0140-6736(12)60240-2 . PMID   22579043. S2CID   8212325.
  57. ↑ Pathirana TI, Jackson CA (April 2018). "Socioeconomic status and multimorbidity: a systematic review and meta-analysis". Australian and New Zealand Journal of Public Health. 42 (2): 186–194. doi: 10.1111/1753-6405.12762 . hdl: 10072/384397 . PMID   29442409. S2CID   4754463.
  58. ↑ Afshar S, Roderick PJ, Kowal P, Dimitrov BD, Hill AG (August 2015). "Multimorbidity and the inequalities of global ageing: a cross-sectional study of 28 countries using the World Health Surveys". BMC Public Health. 15: 776. doi: 10.1186/s12889-015-2008-7 . PMC   4534141 . PMID   26268536.
  59. ↑ Hariri P, Clarke R, Bragg F, Chen Y, Guo Y, Yang L, et al. (January 2022). "Frequency and types of clusters of major chronic diseases in 0.5 million adults in urban and rural China". Journal of Multimorbidity and Comorbidity. 12: 26335565221098327. doi:10.1177/26335565221098327. PMC   9125108 . PMID   35615751.
  60. ↑ The Lancet (April 2018). "Making more of multimorbidity: an emerging priority". Lancet. 391 (10131): 1637. doi: 10.1016/S0140-6736(18)30941-3 . PMID   29726322.
  61. ↑ Pearson-Stuttard J, Ezzati M, Gregg EW (December 2019). "Multimorbidity-a defining challenge for health systems". The Lancet. Public Health. 4 (12): e599–e600. doi:10.1016/S2468-2667(19)30222-1. hdl: 10044/1/75127 . PMID   31812234. S2CID   208955266.
  62. ↑ Kuan V, Denaxas S, Patalay P, Nitsch D, Mathur R, Gonzalez-Izquierdo A, et al. (January 2023). "Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study". The Lancet. Digital Health. 5 (1): e16–e27. doi: 10.1016/S2589-7500(22)00187-X . PMID   36460578. S2CID   254129048.
  63. ↑ Garmany A, Yamada S, Terzic A (September 2021). "Longevity leap: mind the healthspan gap". npj Regenerative Medicine. 6 (1): 57. doi:10.1038/s41536-021-00169-5. PMC   8460831 . PMID   34556664.
  64. ↑ Farrelly C (November 2022). "Aging, Equality and the Human Healthspan". HEC Forum: 1–19. doi:10.1007/s10730-022-09499-3. PMC   9644010 . PMID   36348214.
  65. 1 2 3 4 Multiple long-term conditions (multimorbidity) and inequality- addressing the challenge: insights from research (Report). National Institute for Health Research. 20 September 2023. doi:10.3310/nihrevidence_59977.
  66. ↑ Kantilafti, Maria; Giannakou, Konstantinos; Chrysostomou, Stavri (6 July 2023). Alahdab, Fares (ed.). "Multimorbidity and food insecurity in adults: A systematic review and meta-analysis". PLOS ONE. 18 (7): e0288063. Bibcode:2023PLoSO..1888063K. doi: 10.1371/journal.pone.0288063 . ISSN   1932-6203. PMC   10325088 . PMID   37410753.
  67. ↑ Álvarez-Gálvez, Javier; Ortega-Martín, Esther; Carretero-Bravo, Jesús; Pérez-Muñoz, Celia; Suárez-Lledó, Víctor; Ramos-Fiol, Begoña (27 March 2023). "Social determinants of multimorbidity patterns: A systematic review". Frontiers in Public Health. 11. doi: 10.3389/fpubh.2023.1081518 . ISSN   2296-2565. PMC   10084932 . PMID   37050950.
  68. ↑ Fleitas Alfonzo, Ludmila; King, Tania; You, Emily; Contreras-Suarez, Diana; Zulkelfi, Syafiqah; Singh, Ankur (23 February 2022). "Theoretical explanations for socioeconomic inequalities in multimorbidity: a scoping review". BMJ Open. 12 (2): e055264. doi:10.1136/bmjopen-2021-055264. ISSN   2044-6055. PMC   8882654 . PMID   35197348.
  69. ↑ Pathirana, Thanya I.; Jackson, Caroline A. (14 February 2018). "Socioeconomic status and multimorbidity: a systematic review and meta-analysis". Australian and New Zealand Journal of Public Health. 42 (2): 186–194. doi: 10.1111/1753-6405.12762 . hdl: 10072/384397 . PMID   29442409. S2CID   4754463.
  70. ↑ Ingram, Elizabeth; Ledden, Sarah; Beardon, Sarah; Gomes, Manuel; Hogarth, Sue; McDonald, Helen; Osborn, David P.; Sheringham, Jessica (1 March 2021). "Household and area-level social determinants of multimorbidity: a systematic review". J Epidemiol Community Health. 75 (3): 232–241. doi:10.1136/jech-2020-214691. ISSN   0143-005X. PMC   7892392 . PMID   33158940.
  71. ↑ Woodward, Abi; Davies, Nathan; Walters, Kate; Nimmons, Danielle; Stevenson, Fiona; Protheroe, Joanne; Chew-Graham, Carolyn A.; Armstrong, Megan (21 February 2023). Sagtani, Reshu Agrawal (ed.). "Self-management of multiple long-term conditions: A systematic review of the barriers and facilitators amongst people experiencing socioeconomic deprivation". PLOS ONE. 18 (2): e0282036. Bibcode:2023PLoSO..1882036W. doi: 10.1371/journal.pone.0282036 . ISSN   1932-6203. PMC   9942951 . PMID   36809286.
  72. ↑ Barnett, Karen; Mercer, Stewart W; Norbury, Michael; Watt, Graham; Wyke, Sally; Guthrie, Bruce (10 May 2012). "Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study". The Lancet. 380 (9836): 37–43. doi: 10.1016/S0140-6736(12)60240-2 . PMID   22579043.
  73. ↑ Head, Anna; Fleming, Kate; Kypridemos, Chris; Schofield, Pieta; Pearson-Stuttard, Jonathan; O'Flaherty, Martin (21 July 2021). "Inequalities in incident and prevalent multimorbidity in England, 2004–19: a population-based, descriptive study". The Lancet Healthy Longevity. 2 (8): e489–e497. doi: 10.1016/S2666-7568(21)00146-X . PMID   36097998. S2CID   237719820.
  74. ↑ Charlton, Judith; Rudisill, Caroline; Bhattarai, Nawaraj; Gulliford, Martin (October 2013). "Impact of deprivation on occurrence, outcomes and health care costs of people with multiple morbidity". Journal of Health Services Research & Policy. 18 (4): 215–223. doi:10.1177/1355819613493772. ISSN   1355-8196. PMC   3808175 . PMID   23945679.
  75. ↑ Hayanga, Brenda; Stafford, Mai; Bécares, Laia (27 January 2023). "Ethnic inequalities in multiple long-term health conditions in the United Kingdom: a systematic review and narrative synthesis". BMC Public Health. 23 (1): 178. doi: 10.1186/s12889-022-14940-w . ISSN   1471-2458. PMC   9879746 . PMID   36703163.
  76. ↑ Verest, Wim J G M; Galenkamp, Henrike; Spek, Bea; Snijder, Marieke B; Stronks, Karien; van Valkengoed, Irene G M (1 August 2019). "Do ethnic inequalities in multimorbidity reflect ethnic differences in socioeconomic status? The HELIUS study". European Journal of Public Health. 29 (4): 687–693. doi:10.1093/eurpub/ckz012. ISSN   1101-1262. PMC   6660190 . PMID   30768174.
  77. ↑ Mathur, Rohini; Hull, Sally A; Badrick, Ellena; Robson, John (26 April 2011). "Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management". British Journal of General Practice. 61 (586): e262–e270. doi:10.3399/bjgp11X572454. ISSN   0960-1643. PMC   3080231 . PMID   21619750.
  78. ↑ "Quantifying health inequalities in England". www.health.org.uk. Retrieved 28 September 2023.
  79. ↑ Stafford, Mai; Knight, Hannah; Hughes, Jay; Alarilla, Anne; Mondor, Luke; Pefoyo Kone, Anna; Wodchis, Walter P.; Deeny, Sarah R. (1 April 2022). Torén, Kjell (ed.). "Associations between multiple long-term conditions and mortality in diverse ethnic groups". PLOS ONE. 17 (4): e0266418. Bibcode:2022PLoSO..1766418S. doi: 10.1371/journal.pone.0266418 . ISSN   1932-6203. PMC   8974956 . PMID   35363804.
  80. ↑ Saunders, Catherine L; MacCarthy, Sarah; Meads, Catherine; Massou, Efthalia; Mant, Jonathan; Saunders, Alison M; Elliott, Marc N (October 2021). "Long-term conditions among sexual minority adults in England: evidence from a cross-sectional analysis of responses to the English GP Patient Survey". BJGP Open. 5 (5): BJGPO.2021.0067. doi:10.3399/BJGPO.2021.0067. ISSN   2398-3795. PMC   8596314 . PMID   34465579.
  81. ↑ Caceres, Billy A.; Travers, Jasmine; Sharma, Yashika (June 2021). "Differences in Multimorbidity among Cisgender Sexual Minority and Heterosexual Adults: Investigating Differences across Age-Groups". Journal of Aging and Health. 33 (5–6): 362–376. doi:10.1177/0898264320983663. ISSN   0898-2643. PMC   8122030 . PMID   33382014.
  82. ↑ Han, Benjamin H.; Duncan, Dustin T.; Arcila-Mesa, Mauricio; Palamar, Joseph J. (4 August 2020). "Co-occurring mental illness, drug use, and medical multimorbidity among lesbian, gay, and bisexual middle-aged and older adults in the United States: a nationally representative study". BMC Public Health. 20 (1): 1123. doi: 10.1186/s12889-020-09210-6 . ISSN   1471-2458. PMC   7401198 . PMID   32746891.
  83. ↑ "Research funders publish framework to tackle multiple long-term conditions". The Academy of Medical Sciences. Retrieved 28 June 2022.
  84. ↑ Cross-funder multimorbidity research framework (Report). The Academy of Medical Sciences. June 2020.
  85. ↑ Taylor RS, Singh S (May 2020). "Personalised rehabilitation for cardiac and pulmonary patients with multimorbidity: Time for implementation?". European Journal of Preventive Cardiology. 28 (16): e19–e23. doi: 10.1177/2047487320926058 . PMID   33611479.
  86. ↑ Carlesso LC, Skou ST, Tang LH, Simonÿ C, Brooks D (February 2020). "Multimorbidity: Making the Case for an End to Disease-Specific Rehabilitation". Physiotherapy Canada. Physiotherapie Canada. 72 (1): 1–3. doi:10.3138/ptc-72-1-gee. PMC   8330980 . PMID   34385742. S2CID   214155787.
  87. ↑ "The PERFORM trial". University of Leicester. Retrieved 5 February 2023.
  88. ↑ Bricca A, Jäger M, Dideriksen M, Rasmussen H, Nyberg M, Pedersen JR, et al. (December 2022). "Personalised exercise therapy and self-management support for people with multimorbidity: Development of the MOBILIZE intervention". Pilot and Feasibility Studies. 8 (1): 244. doi: 10.1186/s40814-022-01204-y . PMC   9717541 . PMID   36461048.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.